secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001736730-26-000021
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 appoints Michael MacLean to Board, effective April 1, 2026
----------------------------------------------------------------

- Michael MacLean, former CFO of Avidity Biosciences, joins as Class III director; board expands to 9 members.
- MacLean appointed to Audit and Compensation Committees; will receive standard director compensation.
- Board amended non-employee director compensation policy: new directors granted options for 56,000 shares vesting over 3 years.
- MacLean brings over 35 years of financial leadership in biotech, including roles at Avidity, Akcea, PureTech, and Biogen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673026000021/0001736730-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673026000021/camp-20260318.htm
  HTML page:      https://secwatch.observer/filing/0001736730-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer